Market Overview

UPDATE: JMP Securities Places BioCryst Pharmaceuticals PT Under Review, Awaiting Details


In a report published Monday, JMP Securities analyst Liisa Bayko reiterated Market Perform on BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), placing target price under review while awaiting details on upcoming programs that could affect it.

According to the report, “BCRX provided an update on data flow from its HAE program, including data presentations on kallikrein inhibitor, BCX4161, at AAAAI in late February/early March and data from the 28-day proof-of-concept study in 1H14, which we view as a key value driver for the company. BioCryst has also profiled its second generation kallikrein inhibitors, which have the expected benefits of better bio-availability (at least 5x BCX4161) and selectivity (at least 4x more selective against tissue factor VII). We anticipate that one of these compounds will move into human development in 1H15. BioCryst is also planning to leverage its drug discovery efforts into a second orphan disease in 2H14. We recommend shares of BioCryst into potentially transformative Phase 2a data.”

BCRX closed Friday at $9.99.

Latest Ratings for BCRX

May 2019DowngradesOutperformSector Perform
Apr 2019MaintainsEqual-WeightEqual-Weight
Apr 2019MaintainsMarket OutperformMarket Outperform

View More Analyst Ratings for BCRX
View the Latest Analyst Ratings

Posted-In: JMP Securities Liisa BaykoAnalyst Color Reiteration Analyst Ratings


Related Articles (BCRX)

View Comments and Join the Discussion!

Latest Ratings

WEEDCantor FitzgeraldMaintains18.9
TGTXCantor FitzgeraldMaintains19.0
SPLKCleveland ResearchDowngrades
IQVWolfe ResearchUpgrades
PRAHWolfe ResearchUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

UPDATE: JMP Securities Reiterates Market Perform on Alnylam Pharmaceuticals on Therapeutic Candidates

UPDATE: JP Morgan Reinstates Coverage on NCR Corporation After Period of Restriction